Table 1.
Ability of osteopontin, soluble mesothelin and megakaryocyte potentiating factor to distinguish healthy asbestos-exposed subjects from malignant mesothelioma patients.
| Studies | N° | Sample | Biomarker cut-off (ng/mL) | Sensitivity % | Specificity % | AUC |
|---|---|---|---|---|---|---|
| OPN | ||||||
| Pass et al. [45] | 193 | serum | 43.3 | 77.6 | 85.5 | 0.89 (0.83–0.93) |
| Paleari et al. [55] | 94 | plasma | 60.8 | 40.0 | 100.0 | 0.60 (0.47–0.72) |
| Grigoriu et al. [52] | 208 | serum | 68.0 | 95.0 | 50.0 | 0.74 (0.68–0.79) |
| Creany et al. [74] | 107 | serum | 18.0 | 47.0 | 95.0 | 0.76 (0.67–0.85) |
| SMRPs | ||||||
| Grigoriu et al. [52] | 208 | serum | 1.7 | 40.0 | 100.0 | 0.74 (0.68–0.80) |
| Scherpereel et al. [61] | 137 | serum | 1.1 | 71.7 | 69.8 | 0.79 (0.73–0.85) |
| Rodriguez et al. [65] | 362 | serum | 1.1 | 24.0 | 97.2 | 0.75 (0.68–0.83) |
| Amati et al. [24] | 170 | plasma | 1.0 | 90.0 | 78.0 | 0.93 (0.88–0.97) |
| Iwahori et al. [66] | 121 | serum | 93.5 | 59.3 | 86.2 | 0.71 |
| Beyer et al. [67] | 497 | serum | 1.0 | 68.2 | 77.0 | – |
| Cristaudo et al. [68] | 369 | serum | 1.0 | 68.2 | 80.5 | 0.77 (0.71–0.83) |
| Creany et al. [74] | 107 | serum | 1.6 | 73.0 | 95.0 | 0.92 (0.87–0.97) |
| Hollevoet et al. [75] | 507 | serum | 2.0 | – | 64.0 | 0.87 |
| Creaney et al. [77] | 233 | serum | 1.4 | – | 67.0 | 0.77 |
| MPF | ||||||
| Iwahori et al. [65] | 121 | serum | 19.1 | 74.1 | 90.4 | 0.88 |
| Creany et al. [74] | 107 | serum | 1.0 | 34.0 | 95.0 | 0.61 (0.51–0.72) |
| Hollevoet et al. [75] | 507 | serum | 12.4 | – | 68.0 | 0.85 |
Osteopontin OPN, soluble mesothelin-related peptides SMRPs, megakaryocyte potentiating factor MPF, area under curve AUC.